Therapeutic Arsenal against Leishmaniases: A Review

References (114)

1. 1 Studies in Natural Products Chemistry [DOI]
2. 2 Oral Miltefosine for Indian Visceral Leishmaniasis [DOI]
3. 3 3. Visceral leishmaniasis [DOI]
4. 4 Pentavalent Antimonials: New Perspectives for Old Drugs [DOI]
5. 5 A review of natural products with antileishmanial activity [DOI]
6. 6 Plant natural products with leishmanicidal activity. [DOI]
7. 7 Leishmaniasis: new approaches to disease control [DOI]
8. 8 Challenges and new discoveries in the treatment of leishmaniasis [DOI]
9. 9 Luteolin, an Abundant Dietary Component is a Potent Anti-leishmanial Agent that Acts by Inducing Topoisomerase II-mediated Kinetoplast DNA Cleavage Leading to Apoptosis [DOI]
10. 10 Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012 [DOI]
11. 11 Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use [DOI]
12. 12 Miltefosine – discovery of the antileishmanial activity of phospholipid derivatives [DOI]
13. 13 The Pharmacology of Leishmaniasis [DOI]
14. 14 One pot synthesis of gold nanoparticles and application in chemotherapy of wild and resistant type visceral leishmaniasis [DOI]
15. 15 Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance [DOI]
16. 16 Pancreatitis Induced by Pentavalent Antimonial Agents During Treatment of Leishmaniasis [DOI]
17. 17 The Reemergence of Visceral Leishmaniasis in Brazil [DOI]
18. 18 Pentavalent antimonials: old drugs for new diseases [DOI]
19. 19 In vitro antileishmanial, antiplasmodial and cytotoxic activities of phenolics and triterpenoids from Baccharis dracunculifolia D. C. (Asteraceae) [DOI]
20. 20 A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis [DOI]
21. 21 Quercitrin: An Antileishmanial Flavonoid Glycoside fromKalanchoe pinnata [DOI]
22. 22 Alkaloids: Future prospective to combat leishmaniasis [DOI]
23. 23 Amphotericin B toxicity and lethality: a tale of two channels [DOI]
24. 24 Leishmaniasis phytotherapy. Nature's leadership against an ancient disease [DOI]
25. 25 Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis [DOI]
26. 26 In vitro Leishmanicidal activity of naturally occurring chalcones [DOI]
27. 27 Leishmanicidal, Antiplasmodial and Cytotoxic Activity of Indole Alkaloids from Corynanthe pachyceras [DOI]
28. 28 In vitro and in vivo antileishmanial activities of a Brazilian green propolis extract [DOI]
29. 29 Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar) [DOI]
30. 30 Leishmanicidal activity of amphotericin B encapsulated in PLGA–DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice [DOI]
31. 31 The antitumoral, trypanocidal and antileishmanial activities of extract and alkaloids isolated from Duguetia furfuracea [DOI]
32. 32 In vitro activity of Tridax procumbens against promastigotes of Leishmania mexicana [DOI]
33. 33 Antileishmanial sesquiterpene lactones from Pseudelephantopus spicatus, a traditional remedy from the Chayahuita Amerindians (Peru). Part III [DOI]
34. 34 Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes [DOI]
35. 35 In vitro antileishmanial and antitrypanosomal activities of five medicinal plants from Burkina Faso [DOI]
36. 36 Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis [DOI]
37. 37 Neutron diffraction studies of the interaction between amphotericin B and lipid-sterol model membranes [DOI]
38. 38 Characterization of the Antimonial Antileishmanial Agent Meglumine Antimonate (Glucantime) [DOI]
39. 39 Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes [DOI]
40. 40 American tegumentary leishmaniasis: direct species identification of Leishmania in non-invasive clinical samples [DOI]
41. 41 Cytotoxic and Leishmanicidal Aminoglycosteroids and Aminosteroids from Holarrhena curtisii [DOI]
42. 42 A review of Leishmaniasis in Eastern Africa [DOI]
43. 43 Old World Leishmania infantum Cutaneous Leishmaniasis Unresponsive to Liposomal Amphotericin B Treated With Topical Imiquimod [DOI]
44. 44 Crucial CD8+ T-lymphocyte cytotoxic role in amphotericin B nanospheres efficacy against experimental visceral leishmaniasis [DOI]
45. 45 4-Quinolinone alkaloids from Dictyoloma peruviana [DOI]
46. 46 Effect of renal impairment on the pharmacokinetics of antimony in hamsters [DOI]
47. 47 In vitro cytocidal effects on Trypanosoma brucei and inhibition of Leishmania major GP63 by peptidomimetic metalloprotease inhibitors [DOI]
48. 48 In-vitro and in-vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis [DOI]
49. 49 Efeito leishmanicida in vitro de Stachytarpheta cayennensis (Rich.) Vahl (Verbenaceae) [DOI]
50. 50 Amphotericin B-Induced Nephrotoxicity [DOI]
51. 51 Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs [DOI]
52. 52 Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis [DOI]
53. 53 Amphotericin B: side effects and toxicity [DOI]
54. 54 The leishmaniases as emerging and reemerging zoonoses [DOI]
55. 55 Antitrypanosomal and Antileishmanial Activities of Flavonoids and Their Analogues: In Vitro, In Vivo, Structure-Activity Relationship, and Quantitative Structure-Activity Relationship Studies [DOI]
56. 56 Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World [DOI]
57. 57 Recent advances in leishmaniasis treatment [DOI]
58. 58 Carrier effects on biological activity of amphotericin B [DOI]
59. 59 Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? [DOI]
60. 60 Liposomal amphotericin B and leishmaniasis: Dose and response [DOI]
61. 61 Antileishmanial Activity of the Terpene Nerolidol [DOI]
62. 62 Reactive Oxygen Species Production and Mitochondrial Dysfunction Contribute to Quercetin Induced Death in Leishmania amazonensis [DOI]
63. 63 Leishmaniasis, an emerging infection in travelers [DOI]
64. 64 Cutaneous and Mucocutaneous Leishmaniasis [DOI]
65. 65 The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata [DOI]
66. 66 A Pyrimidine-β-carboline and Other Alkaloids from Annona foetida with Antileishmanial Activity [DOI]
67. 67 The leishmanicidal flavonols quercetin and quercitrin target Leishmania (Leishmania) amazonensis arginase [DOI]
68. 68 Nano-based antileishmanial agents: A toxicological study on nanoparticles for future treatment of cutaneous leishmaniasis [DOI]
69. 69 Successful Treatment of Drug‐Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator [DOI]
70. 70 Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and S‐28463: Efficacy and Mode of Action [DOI]
71. 71 Axenically Grown Amastigotes of Leishmania infantum Used as an In Vitro Model To Investigate the Pentavalent Antimony Mode of Action [DOI]
72. 72 Leishmaniasis as an Emerging Infection [DOI]
73. 73 Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions [DOI]
74. 74 Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam [DOI]
75. 75 Efficacy of Orally Administered 2-Substituted Quinolines in Experimental Murine Cutaneous and Visceral Leishmaniases [DOI]
76. 76 Oral Metabolism and Efficacy ofKalanchoe pinnataFlavonoids in a Murine Model of Cutaneous Leishmaniasis [DOI]
77. 77 Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study [DOI]
78. 78 Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: A preliminary study [DOI]
79. 79 Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds of Dimorphandra gardneriana and Platymiscium floribundum, native plants from Caatinga biome [DOI]
80. 80 Comparative Activities of the Triterpene Saponin Maesabalide III and Liposomal Amphotericin B (AmBisome) againstLeishmania donovaniin Hamsters [DOI]
81. 81 Novel methods for the encapsulation of meglumine antimoniate into liposomes [DOI]
82. 82 Natural Terpenoids from Ambrosia Species Are Active In Vitro and In Vivo against Human Pathogenic Trypanosomatids [DOI]
83. 83 Antiprotozoal Activity of Essential Oils
84. 84 Activity of Cuban Plants Extracts againstLeishmania amazonensis [DOI]
85. 85 Outbreak of Cutaneous Leishmaniasis in Fuenlabrada, Madrid [DOI]
86. 86 TREATMENT OF VISCERAL LEISHMANIASIS IN 2004 [DOI]
87. 87 Isolation of Bis-Indole Alkaloids with Antileishmanial and Antibacterial Activities fromPerschiera van heurkii(Syn.Tabernaemontana van heurkii) [DOI]
88. 88 Ambisome plus miltefosine for Indian patients with kala-azar [DOI]
89. 89 Minor Alkaloids From Guatteria dumetorum with Antileishmanial Activity [DOI]
90. 90 Enhanced oral delivery of antimony from meglumine antimoniate/β-cyclodextrin nanoassemblies [DOI]
91. 91 American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report [DOI]
92. 92 In vitro antileishmanial properties of new flavonoids against Leishmania donovani [DOI]
93. 93 Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India [DOI]
94. 94 Layered double hydroxides (LDHs) as carrier of antimony aimed for improving leishmaniasis chemotherapy [DOI]
95. 95 Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS [DOI]
96. 96 Efeito de uma formulação hidrofílica de paromomicina tópica na leishmaniose cutânea em pacientes com contra-indicações de tratamento com antimonial pentavalente [DOI]
97. 97 Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis [DOI]
98. 98 NATURAL PRODUCTS IN ANTILEISHMANIAL DRUG DISCOVERY: A REVIEW
99. 99 Association of Liposome-Encapsulated Trivalent Antimonial with Ascorbic Acid: An Effective and Safe Strategy in the Treatment of Experimental Visceral Leishmaniasis [DOI]
100. 100 Diabetes melutus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis [DOI]
101. 101 Advances in leishmaniasis [DOI]
102. 102 A PHASE II DOSE-INCREASING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN KENYA [DOI]
103. 103 A study of the excretion of organic antimonials using a polarographic procedure [DOI]
104. 104 In vitro activity of C20-diterpenoid alkaloid derivatives in promastigotes and intracellular amastigotes of Leishmania infantum [DOI]
105. 105 Dihydrobetulinic Acid Induces Apoptosis in Leishmania donovani by Targeting DNA Topoisomerase I and II: Implications in Antileishmanial Therapy [DOI]
106. 106 Oral Delivery of Meglumine Antimoniate-β-Cyclodextrin Complex for Treatment of Leishmaniasis [DOI]
107. 107 [Treatment of visceral leishmaniasis].
108. 108 Re-emergence of visceral leishmaniasis in Gujarat, India.
109. 109 Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children.
110. 110 Mechanism of interaction of sitamaquine with Leishmania donovani [DOI]
111. 111 Plant-Derived Natural Products for the Treatment of Leishmaniasis [DOI]
112. 112 ANTIMONY IN MEDICINE [DOI]
113. 113 A Review of Leishmaniasis in Eastern Africa [DOI]
114. 114 Amphotericin B: A Commentary on Its Role as an Antifungal Agent and as a Comparative Agent in Clinical Trials [DOI]

Cited by 1

Related research

• Metal Based α-glucosidase Inhibitors: Synthesis, Characterization and α-glucosidase Inhibition Activity of Transition Metal Complexes — shares topic coverage
• Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
• Mantle Cell Lymphoma of Gastrointestinal Tract as a Lead Point for Intussusception: A Case Report — shares topic coverage
• Antimalarial Drug Resistance: An Existential Burden for the Developing World — shares topic coverage
• Feline Mesenteric form of Multinodal Lymphoma: A Case Report — shares topic coverage